Download PDF
Der Nuklearmediziner 2015; 38(02): 83-88
DOI: 10.1055/s-0035-1550006
Diagnostik und Therapie des Prostatakarzinoms – Neue Entwicklungen
© Georg Thieme Verlag KG Stuttgart · New York

Die perkutane Strahlentherapie als primäre Option der Therapie des lokal begrenzten Prostatakarzinoms

External-beam Radiotherapy as Primary Treatment Option for Localized Prostate Cancer
D. Bartkowiak
1   Klinik für Strahlentherapie und Radioonkologie, Universitätsklinikum Ulm
,
D. Bottke
1   Klinik für Strahlentherapie und Radioonkologie, Universitätsklinikum Ulm
,
T. Wiegel
1   Klinik für Strahlentherapie und Radioonkologie, Universitätsklinikum Ulm
› Author Affiliations
Further Information

Publication History

Publication Date:
09 June 2015 (online)

Also available at
    Permissions and Reprints

Zusammenfassung

Zur Behandlung des lokal begrenzten Prostatakarzinoms (PCa) werden die radikale Prostatektomie (RP), perkutane Strahlentherapie (RT), die permanente Seed-Implantation (PSI) oder die Active Surveillance (AS) als kurative Therapie eingesetzt. Unter Berücksichtigung der aktuellen deutschen S3-Leitlinie und der EAU-Guideline fassen wir das stadienabhängige Prozedere aus der Sicht der Strahlentherapie zusammen.

Beim lokal begrenzten niedrig-Risisko PCa ist bisher nicht geklärt, welche Behandlung die besten Resultate erbringt, wenn Heilungschance, Nebenwirkungsrisiko und Patientenwünsche berücksichtigt werden. Für diese Patientengruppe werden in der PREFERE Studie die RP, RT, PSI und AS vergleichend untersucht.

Beim PCa mit intermediärem oder mit hohem Risiko-Profil sind die kombinierte RT+hormonelle Behandlung (HT) oder die RP indiziert. Mit der frühen Salvage-RT, bei einem PSA unter 0,5 ng/ml, besteht nach post-RP biochemischem Rezidiv eine zweite Heilungschance.

Abstract

For localized prostate cancer (PCa), radical prostatectomy (RP), external-beam radiotherapy (RT), permanent seed implantation (PSI) or active surveillance (AS) are curative treatment options. Referring to the German S3-Guideline and the EAU-Guideline, we summarize stage-specific procedures from the perspective of radiotherapy.

For low-risk localized prostate cancer, it is not clear which treatment gives the best results if cure rates, risk of side effects and patients‘ preferences are taken into account. For these patients, the PREFERE trial will compare RP, RT, PSI and AS.

For PCa with intermediate or high-risk profile, combined RT and hormonal treatment or RP are indicated. Early salvage radiotherapy at a PSA below 0.5 ng/ml offers a second chance of cure in case of post-RP biochemical recurrence.

Key words

localized prostate cancer - stage specific treatment - definitive radiotherapy - adjuvant radiotherapy - salvage radiotherapy
 

  • Literatur

  • 1 Audenet F, Seringe E, Drouin SJ et al. Persistently elevated prostate-specific antigen at six weeks after radical prostatectomy helps in early identification of patients who are likely to recur. World J Urol 2012; 30: 239-244
    CrossrefPubMedGoogle Scholar
  • 2 Beckendorf V, Guerif S, Le Prise E et al. 70 Gy versus 80 Gy in localized prostate cancer: 5-year results of GETUG 06 randomized trial. Int J Radiat Oncol Biol Phys 2011; 80: 1056-1063
    CrossrefPubMedGoogle Scholar
  • 3 Bernard Jr JR, Buskirk SJ, Heckman MG et al. Salvage radiotherapy for rising prostate-specific antigen levels after radical prostatectomy for prostate cancer: dose-response analysis. Int J Radiat Oncol Biol Phys 2010; 76: 735-740
    CrossrefPubMedGoogle Scholar
  • 4 Bill-Axelson A, Holmberg L, Garmo H et al. Radical prostatectomy or watchful waiting in early prostate cancer. N Engl J Med 2014; 370: 932-942
    CrossrefPubMedGoogle Scholar
  • 5 Bolla M, van Poppel H, Collette L et al. Postoperative radiotherapy after radical prostatectomy: a randomised controlled trial (EORTC trial 22911). Lancet 2005; 366: 572-578
    CrossrefPubMedGoogle Scholar
  • 6 Bolla M, van Poppel H, Tombal B et al. Postoperative radiotherapy after radical prostatectomy for high-risk prostate cancer: long-term results of a randomised controlled trial (EORTC trial 22911). Lancet 2012; 380: 2018-2027
    CrossrefPubMedGoogle Scholar
  • 7 Bottke D, Bartkowiak D, Schrader M et al. Radiotherapy after radical prostatectomy: immediate or early delayed?. Strahlenther Onkol 2012; 188: 1096-1101
    CrossrefPubMedGoogle Scholar
  • 8 Briganti A, Joniau S, Gandaglia G et al. Patterns and predictors of early biochemical recurrence after radical prostatectomy and adjuvant radiation therapy in men with pT3N0 prostate cancer: implications for multimodal therapies. Int J Radiat Oncol Biol Phys 2013; 87: 960-967
    CrossrefPubMedGoogle Scholar
  • 9 Briganti A, Wiegel T, Joniau S et al. Early Salvage Radiation Therapy Does Not Compromise Cancer Control in Patients with pT3N0 Prostate Cancer After Radical Prostatectomy: Results of a Match-controlled Multi-institutional Analysis. Eur Urol 2012; 62: 472-487
    CrossrefPubMedGoogle Scholar
  • 10 Budiharto T, Perneel C, Haustermans K et al. A multi-institutional analysis comparing adjuvant and salvage radiation therapy for high-risk prostate cancer patients with undetectable PSA after prostatectomy. Radiother Oncol 2010; 97: 474-479
    CrossrefPubMedGoogle Scholar
  • 11 Chua B, Min M, Wood M et al. Implementation of an image guided intensity-modulated protocol for post-prostatectomy radiotherapy: planning data and acute toxicity outcomes. Journal of medical imaging and radiation oncology 2013; 57: 482-489
    CrossrefPubMedGoogle Scholar
  • 12 Dearnaley DP, Jovic G, Syndikus I et al. Escalated-dose versus control-dose conformal radiotherapy for prostate cancer: long-term results from the MRC RT01 randomised controlled trial. Lancet Oncol 2014; 15: 464-473
    CrossrefPubMedGoogle Scholar
  • 13 Denham JW, Steigler A, Lamb DS et al. Short-term neoadjuvant androgen deprivation and radiotherapy for locally advanced prostate cancer: 10-year data from the TROG 96.01 randomised trial. Lancet Oncol 2011; 12: 451-459
    CrossrefPubMedGoogle Scholar
  • 14 Elliott SP, Wilt TJ, Kuntz KM. Projecting the clinical benefits of adjuvant radiotherapy versus observation and selective salvage radiotherapy after radical prostatectomy: a decision analysis. Prostate Cancer Prostatic Dis 2011; 14: 270-277
    CrossrefPubMedGoogle Scholar
  • 15 Geinitz H, Riegel MG, Thamm R et al. Outcome after conformal salvage radiotherapy in patients with rising prostate-specific antigen levels after radical prostatectomy. Int J Radiat Oncol Biol Phys 2012; 82: 1930-1937
    CrossrefPubMedGoogle Scholar
  • 16 Giovacchini G, Picchio M, Parra RG et al. Prostate-specific antigen velocity versus prostate-specific antigen doubling time for prediction of 11C choline PET/CT in prostate cancer patients with biochemical failure after radical prostatectomy. Clin Nucl Med 2012; 37: 325-331
    CrossrefPubMedGoogle Scholar
  • 17 Goenka A, Magsanoc JM, Pei X et al. Improved toxicity profile following high-dose postprostatectomy salvage radiation therapy with intensity-modulated radiation therapy. Eur Urol 2011; 60: 1142-1148
    CrossrefPubMedGoogle Scholar
  • 18 Grimm PD, Blasko JC, Sylvester JE et al. 10-year biochemical (prostate-specific antigen) control of prostate cancer with (125)I brachytherapy. Int J Radiat Oncol Biol Phys 2001; 51: 31-40
    PubMedGoogle Scholar
  • 20 Heidenreich A, Bastian PJ, Bellmunt J et al. EAU guidelines on prostate cancer. part 1: screening, diagnosis, and local treatment with curative intent-update 2013. Eur Urol 2014; 65: 124-137
    CrossrefPubMedGoogle Scholar
  • 19 Heidenreich A, Bastian PJ, Bellmunt J et al. EAU guidelines on prostate cancer. Part II: Treatment of advanced, relapsing, and castration-resistant prostate cancer. Eur Urol 2014; 65: 467-479
    CrossrefPubMedGoogle Scholar
  • 21 Jackson WC, Johnson SB, Foster B et al. Combining prostate-specific antigen nadir and time to nadir allows for early identification of patients at highest risk for development of metastasis and death following salvage radiation therapy. Practical radiation oncology 2014; 4: 99-107
    CrossrefPubMedGoogle Scholar
  • 22 Jereczek-Fossa BA, Zerini D, Vavassori A et al. Sooner or later? Outcome analysis of 431 prostate cancer patients treated with postoperative or salvage radiotherapy. Int J Radiat Oncol Biol Phys 2009; 74: 115-125
    CrossrefPubMedGoogle Scholar
  • 23 Jones CU, Hunt D, McGowan DG et al. Radiotherapy and short-term androgen deprivation for localized prostate cancer. N Engl J Med 2011; 365: 107-118
    CrossrefPubMedGoogle Scholar
  • 24 King CR, Kapp DS. Radiotherapy after prostatectomy: is the evidence for dose escalation out there?. Int J Radiat Oncol Biol Phys 2008; 71: 346-350
    CrossrefPubMedGoogle Scholar
  • 25 King CR. The timing of salvage radiotherapy after radical prostatectomy: a systematic review. Int J Radiat Oncol Biol Phys 2012; 84: 104-111
    CrossrefPubMedGoogle Scholar
  • 26 Klotz L, Vesprini D, Sethukavalan P et al. Long-term follow-up of a large active surveillance cohort of patients with prostate cancer. J Clin Oncol 2015; 33: 272-277
    CrossrefPubMedGoogle Scholar
  • 27 Kuban DA, Levy LB, Cheung MR et al. Long-term failure patterns and survival in a randomized dose-escalation trial for prostate cancer. Who dies of disease?. Int J Radiat Oncol Biol Phys 2011; 79: 1310-1317
    CrossrefPubMedGoogle Scholar
  • 28 Lawton CA, Hunt D, Lee WR et al. Long-term results of a phase II trial of ultrasound-guided radioactive implantation of the prostate for definitive management of localized adenocarcinoma of the prostate (RTOG 98-05). Int J Radiat Oncol Biol Phys 2011; 81: 1-7
    CrossrefPubMedGoogle Scholar
  • 29 Leitlinienprogramm Onkologie der AWMF DKeVuDKeV. Interdisziplinäre Leitlinie der Qualität S3 zur Früherkennung, Diagnose und Therapie der verschiedenen Stadien des Prostatakarzinom. 2014 http://leitlinienprogramm-onkologie.de/uploads/tx_sbdownloader/LL_Prostata_Langversion_3.0.pdf
    PubMedGoogle Scholar
  • 30 Lohm G, Lutcke J, Jamil B et al. Salvage radiotherapy in patients with prostate cancer and biochemical relapse after radical prostatectomy: Long-term follow-up of a single-center survey. Strahlenther Onkol 2014; 190: 727-731
    CrossrefPubMedGoogle Scholar
  • 31 Lotan Y, Roehrborn CG. Clearance rates of total prostate specific antigen (PSA) after radical prostatectomy in African-Americans and Caucasians. Prostate Cancer Prostatic Dis 2002; 5: 111-114
    CrossrefPubMedGoogle Scholar
  • 32 Mir MC, Li J, Klink JC et al. Optimal Definition of Biochemical Recurrence After Radical Prostatectomy Depends on Pathologic Risk Factors: Identifying Candidates for Early Salvage Therapy. Eur Urol 2014; 66: 204-210
    CrossrefPubMedGoogle Scholar
  • 33 Ohri N, Dicker AP, Trabulsi EJ et al. Can early implementation of salvage radiotherapy for prostate cancer improve the therapeutic ratio? A systematic review and regression meta-analysis with radiobiological modelling. Eur J Cancer 2012; 48: 837-844
    CrossrefPubMedGoogle Scholar
  • 34 Ost P, De Troyer B, Fonteyne V et al. A matched control analysis of adjuvant and salvage high-dose postoperative intensity-modulated radiotherapy for prostate cancer. Int J Radiat Oncol Biol Phys 2011; 80: 1316-1322
    CrossrefPubMedGoogle Scholar
  • 35 Ost P, Lumen N, Goessaert AS et al. High-dose salvage intensity-modulated radiotherapy with or without androgen deprivation after radical prostatectomy for rising or persisting prostate-specific antigen: 5-year results. Eur Urol 2011; 60: 842-849
    CrossrefPubMedGoogle Scholar
  • 36 Peeters ST, Heemsbergen WD, Koper PC et al. Dose-response in radiotherapy for localized prostate cancer: results of the Dutch multicenter randomized phase III trial comparing 68 Gy of radiotherapy with 78 Gy. J Clin Oncol 2006; 24: 1990-1996
    CrossrefPubMedGoogle Scholar
  • 37 Robert-Koch-Institut. Krebs in Deutschland 2009/2010. 2013 http://www.rki.de/Krebs/DE/Content/Krebsarten/krebsarten_node.html
    PubMedGoogle Scholar
  • 38 Roehl KA, Han M, Ramos CG et al. Cancer progression and survival rates following anatomical radical retropubic prostatectomy in 3,478 consecutive patients: long-term results. J Urol 2004; 172: 910-914
    CrossrefPubMedGoogle Scholar
  • 39 Rossi Jr CJ, Joe Hsu IC, Abdel-Wahab M et al. ACR appropriateness criteria postradical prostatectomy irradiation in prostate cancer. Am J Clin Oncol 2011; 34: 92-98
    CrossrefPubMedGoogle Scholar
  • 40 Shipley WU, Hunt D, Lukka H et al. Initial Report of RTOG 9601: A Phase III Trial in Prostate Cancer: Anti-androgen Therapy (AAT) with Bicalutamide during and after Radiation Therapy (RT) Improves Freedom from Progression and Reduces the Incidence of Metastatic Disease in Patients following Radical Prostatectomy (RP) with pT2-3, N0 Disease, and Elevated PSA Levels. Int J Radiat Oncol Biol Phys 2010; 78: S27
    PubMedGoogle Scholar
  • 41 Siegmann A, Bottke D, Faehndrich J et al. Dose escalation for patients with decreasing PSA during radiotherapy for elevated PSA after radical prostatectomy improves biochemical progression-free survival : Results of a retrospective study. Strahlenther Onkol 2011; 187: 467-472
    CrossrefPubMedGoogle Scholar
  • 42 Stephenson AJ, Bolla M, Briganti A et al. Postoperative radiation therapy for pathologically advanced prostate cancer after radical prostatectomy. Eur Urol 2012; 61: 443-451
    CrossrefPubMedGoogle Scholar
  • 43 Stephenson AJ, Scardino PT, Kattan MW et al. Predicting the outcome of salvage radiation therapy for recurrent prostate cancer after radical prostatectomy. J Clin Oncol 2007; 25: 2035-2041
    CrossrefPubMedGoogle Scholar
  • 44 Stephenson AJ, Wood DP, Kattan MW et al. Location, extent and number of positive surgical margins do not improve accuracy of predicting prostate cancer recurrence after radical prostatectomy. J Urol 2009; 182: 1357-1363
    CrossrefPubMedGoogle Scholar
  • 45 Stone NN, Stock RG, Unger P. Intermediate term biochemical-free progression and local control following 125iodine brachytherapy for prostate cancer. J Urol 2005; 173: 803-807
    CrossrefPubMedGoogle Scholar
  • 46 Thompson I, Thrasher JB, Aus G et al. Guideline for the management of clinically localized prostate cancer: 2007 update. J Urol 2007; 177: 2106-2131
    CrossrefPubMedGoogle Scholar
  • 47 Thompson Jr IM, Tangen CM, Paradelo J et al. Adjuvant radiotherapy for pathologically advanced prostate cancer: a randomized clinical trial. JAMA 2006; 296: 2329-2335
    CrossrefPubMedGoogle Scholar
  • 48 Thompson IM, Tangen CM, Paradelo J et al. Adjuvant radiotherapy for pathological T3N0M0 prostate cancer significantly reduces risk of metastases and improves survival: long-term followup of a randomized clinical trial. J Urol 2009; 181: 956-962
    CrossrefPubMedGoogle Scholar
  • 49 Trabulsi EJ, Valicenti RK, Hanlon AL et al. A multi-institutional matched-control analysis of adjuvant and salvage postoperative radiation therapy for pT3-4N0 prostate cancer. Urology 2008; 72: 1298-1302 discussion 1302-1294
    CrossrefPubMedGoogle Scholar
  • 50 Van der Kwast TH, Bolla M, Van Poppel H et al. Identification of patients with prostate cancer who benefit from immediate postoperative radiotherapy: EORTC 22911. J Clin Oncol 2007; 25: 4178-4186
    CrossrefPubMedGoogle Scholar
  • 51 Wiegel T, Bartkowiak D, Bottke D et al. Adjuvant Radiotherapy Versus Wait-and-See After Radical Prostatectomy: 10-year Follow-up of the ARO 96–02/AUO AP 09/95 Trial. Eur Urol 2014; 66: 243-250
    CrossrefPubMedGoogle Scholar
  • 52 Wiegel T, Bartkowiak D, Bottke D et al. Prostate-Specific Antigen Persistence After Radical Prostatectomy as a Predictive Factor of Clinical Relapse-Free Survival and Overall Survival: 10-Year Data of the ARO 96-02 Trial. Int J Radiat Oncol Biol Phys 2015; 91: 288-294
    CrossrefPubMedGoogle Scholar
  • 53 Wiegel T, Bottke D, Steiner U et al. Phase III postoperative adjuvant radiotherapy after radical prostatectomy compared with radical prostatectomy alone in pT3 prostate cancer with postoperative undetectable prostate-specific antigen: ARO 96-02/AUO AP 09/95. J Clin Oncol 2009; 27: 2924-2930
    CrossrefPubMedGoogle Scholar
  • 54 Wiegel T, Lohm G, Bottke D et al. Achieving an undetectable PSA after radiotherapy for biochemical progression after radical prostatectomy is an independent predictor of biochemical outcome – results of a retrospective study. Int J Radiat Oncol Biol Phys 2009; 73: 1009-1016
    CrossrefPubMedGoogle Scholar
  • 55 Wiegel T, Stöckle M, Bartkowiak D. PREFEREnce-based randomized evaluation of treatment modalities in low or early intermediate-risk prostate cancer. Eur Urol 2015; 67: 1-2
    CrossrefPubMedGoogle Scholar
  • 56 Zietman AL, Bae K, Slater JD et al. Randomized trial comparing conventional-dose with high-dose conformal radiation therapy in early-stage adenocarcinoma of the prostate: long-term results from proton radiation oncology group/american college of radiology 95-09. J Clin Oncol 2010; 28: 1106-1111
    CrossrefPubMedGoogle Scholar